WO2022142914A1 - Nouvelle forme cristalline de midostaurine, son procédé de préparation et son utilisation - Google Patents

Nouvelle forme cristalline de midostaurine, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2022142914A1
WO2022142914A1 PCT/CN2021/133470 CN2021133470W WO2022142914A1 WO 2022142914 A1 WO2022142914 A1 WO 2022142914A1 CN 2021133470 W CN2021133470 W CN 2021133470W WO 2022142914 A1 WO2022142914 A1 WO 2022142914A1
Authority
WO
WIPO (PCT)
Prior art keywords
midostaurin
crystal form
preparation
ethanol
volume ratio
Prior art date
Application number
PCT/CN2021/133470
Other languages
English (en)
Chinese (zh)
Inventor
郑剑锋
施珍娟
李娜
苏笛
陈连蔚
赵美玉
Original Assignee
浙江海正药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江海正药业股份有限公司 filed Critical 浙江海正药业股份有限公司
Publication of WO2022142914A1 publication Critical patent/WO2022142914A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to the field of chemical pharmacy. More specifically, the present invention relates to a new crystal form of midostaurin, a preparation method of the new crystal form and their medicinal uses.
  • PKC Protein kinase C
  • Midostaurin exhibits high anti-proliferative and anti-tumor activity, and its highly selective and potent PKC inhibition results in better clinical outcomes in patients, i.e. delayed or inhibited disease, compared to similarly tolerated regimens It is extremely useful for cancer treatment, especially for breast cancer, colon cancer, ovarian cancer and leukemia.
  • the drug midostaurin is used as an antineoplastic agent, and in general, the preparation of midostaurin is known in the art. However, we know that different crystalline forms of the same drug may differ substantially in some important properties of the drug, and therefore there is a continuing need for new solid forms of midostaurin as well as new methods of preparation.
  • Midostaurin is a derivative of the naturally occurring alkaloid starbactin and has been specifically described in European Patent 0296110, US Patent 5093330.
  • Crystal form II and amorphous form of midostaurin are disclosed in CN101048416A.
  • the crystal form III and crystal form IV of midostaurin are disclosed in CN102639538.
  • the crystal form III has a melting point of 206 ⁇ 10°C and contains about 3.2% of residual solvent or water.
  • the crystal form IV has a melting point of 215 ⁇ 10°C and contains about 6.2% residual solvent or water, the preparation methods of both crystal forms are GAS (gas anti-solvent) recrystallization.
  • WO2018165071A discloses midostaurin crystal forms V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, a total of 12 crystal forms, all of which are solvates, respectively ethyl acetate Ester solvate, hydrate, methyl isobutyl ketone solvate, 4-heptanone solvate, methyl acetate solvate, acetone solvate, ethyl formate solvate, isopropyl acetate solvate, diethyl carbonate Solvate, benzonitrile solvate, butyl acetate solvate, tert-butanol solvate.
  • solvates respectively ethyl acetate Ester solvate, hydrate, methyl isobutyl ketone solvate, 4-heptanone solvate, methyl acetate solvate, acetone solvate,
  • crystal form II the crystal form of midostaurin preparations sold on the market is crystal form II.
  • crystal seeds must be added to induce crystallization during the preparation process, indicating that it is difficult to spontaneously crystallize, and its preparation technology has limitations. difficult to promote.
  • the preparation method of crystal form III and crystal form IV is a supercritical fluid method, which is suitable for laboratory research and difficult to realize industrial operation.
  • the crystal forms V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, etc. are all solvates, which are difficult to be used in preparations.
  • one of the objects of the present invention is to provide a kind of midostaurin crystal forms A, B and C with good chemical and physical stability, and the crystal forms are in physical and chemical stability.
  • it has excellent properties; and the preparation method of the crystal form of the present invention is easy to operate and easy to industrialized production method.
  • the X-ray powder diffraction (XRD) pattern of midostaurin crystal form A of the present invention has characteristic peaks at the following diffraction angles 2 ⁇ : 4.6 ⁇ 0.2°, 6.1 ⁇ 0.2°, 7.1 ⁇ 0.2°, 11.0 ⁇ 0.2 °, 14.1 ⁇ 0.2°, 14.9 ⁇ 0.2°, 15.4 ⁇ 0.2°, 17.3 ⁇ 0.2°, 18.5 ⁇ 0.2°, 21.6 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of midostaurin crystal form A of the present invention further has characteristic peaks at the following 2 ⁇ : 9.3 ⁇ 0.2°, 9.8 ⁇ 0.2°, 12.1 ⁇ 0.2°, 13.2 ⁇ 0.2° , 15.7 ⁇ 0.2°, 17.9 ⁇ 0.2°, 19.6 ⁇ 0.2°, 20.0 ⁇ 0.2°, 22.3 ⁇ 0.2°, 23.4 ⁇ 0.2°, 23.9 ⁇ 0.2°, 25.5 ⁇ 0.2°, 26.5 ⁇ 0.2°, 29.2 ⁇ 0.2° .
  • the midostaurin crystal form A of the present invention has substantially the same X-ray powder diffraction pattern as shown in FIG. 1 .
  • the X-ray powder diffraction pattern has the 2 ⁇ and relative intensity data shown in Table 1 below:
  • Peak number 2 ⁇ (°) Relative Strength(%) 1 4.6 ⁇ 0.2° 39.5 2 6.1 ⁇ 0.2° 100 3 7.1 ⁇ 0.2° 44.7 4 9.3 ⁇ 0.2° 12.8 5 9.8 ⁇ 0.2° 18.7 6 11.0 ⁇ 0.2° 46.3 7 12.1 ⁇ 0.2° 16.7 8 13.2 ⁇ 0.2° 12.6 9 14.1 ⁇ 0.2° 34.1 10 14.9 ⁇ 0.2° 64.5 11 15.4 ⁇ 0.2° 40.9 12 15.7 ⁇ 0.2° 16.7 13 17.3 ⁇ 0.2° 49.3 14 17.9 ⁇ 0.2° 27.1 15 18.5 ⁇ 0.2° 60.3 16 19.6 ⁇ 0.2° 13 17 20.0 ⁇ 0.2° 11.2 18 20.6 ⁇ 0.2° 21.2 19 21.6 ⁇ 0.2° 40.8 20 22.3 ⁇ 0.2° 25.0
  • the midostaurin crystal form A of the present invention has a melting point measured by a melting point apparatus of 196°C.
  • the midostaurin crystal form A of the present invention has substantially the same TGA spectrum as shown in FIG. 2 .
  • Another object of the present invention is to provide a preparation method of midostaurin crystal form A, the method comprises the following steps:
  • the weight-to-volume ratio (g/mL) of midostaurin and benzyl alcohol described in step (1) is 1:2-10.
  • the poor solvent in step (2) is a mixed solvent of ethanol and water, and the volume ratio (mL/mL) of the ethanol and water is 1:1.
  • the volume ratio (mL/mL) of the benzyl alcohol in the step (1) and the poor solvent in the step (2) is 1:6-50.
  • the duration of adding the poor solvent is 5-30min, and the stirring and crystallization time is 1-48h.
  • the present invention also relates to a pharmaceutical composition containing midostaurin crystal form A, the pharmaceutical composition comprising a therapeutically effective amount of midostaurin crystal form A, and one or more pharmaceutically acceptable carriers.
  • the present invention also relates to the use of the pharmaceutical composition containing midostaurin crystal form A and crystal form A for preparing a medicament for treating tumor diseases, and the tumor is preferably breast cancer, colon cancer, ovarian cancer or leukemia.
  • the X-ray powder diffraction (XRD) pattern of midostaurin crystal form B of the present invention has characteristic peaks at the following diffraction angles 2 ⁇ : 4.9 ⁇ 0.2°, 6.5 ⁇ 0.2°, 7.3 ⁇ 0.2°, 12.0 ⁇ 0.2 °, 12.9 ⁇ 0.2°, 14.6 ⁇ 0.2°, 15.7 ⁇ 0.2°, 17.5 ⁇ 0.2°, 18.7 ⁇ 0.2°, 20.6 ⁇ 0.2°, 21.9 ⁇ 0.2°
  • the midostaurin crystal form B of the present invention has substantially the same X-ray powder diffraction pattern as shown in FIG. 3 .
  • the X-ray powder diffraction pattern has the 2 ⁇ and relative intensity data shown in Table 2 below:
  • the midostaurin crystal form B according to the present invention has a melting point of 198°C as measured by a melting point apparatus.
  • the crystal form B of midostaurin according to the present invention has substantially the same TGA spectrum as shown in FIG. 4 .
  • Another object of the present invention is to provide a preparation method of midostaurin crystal form B, the method comprises the following steps:
  • step (2) adding water to the filtrate obtained in step (1) under stirring, and crystallization to obtain midostaurin crystal form B.
  • the mass volume ratio (g/mL) of midostaurin to acetic acid and ethanol mixed solution is 1:50-100, and the volume ratio (mL/mL) of the acetic acid and ethanol is 1:15-30.
  • the volume ratio (mL/mL) of the mixed solution of acetic acid and ethanol in the step (1) to the water in the step (2) is 1:1-5.
  • the crystallization temperature is 0-20° C.
  • the crystallization time is 1-12 h.
  • the present invention also relates to a pharmaceutical composition containing midostaurin crystal form B, the pharmaceutical composition comprising a therapeutically effective amount of midostaurin crystal form B, and one or more pharmaceutically acceptable carriers.
  • the present invention also relates to the use of the pharmaceutical composition containing midostaurin crystal form B and crystal form B for preparing a medicine for treating tumor diseases, the tumor is preferably breast cancer, colon cancer, ovarian cancer or leukemia.
  • the X-ray powder diffraction (XRD) pattern of midostaurin crystal form C according to the present invention has characteristic peaks at the following diffraction angles 2 ⁇ : 5.4 ⁇ 0.2°, 5.9 ⁇ 0.2°, 6.3 ⁇ 0.2°, 6.9 ⁇ 0.2 °, 7.4 ⁇ 0.2°, 8.6 ⁇ 0.2°, 12.4 ⁇ 0.2°, 16.9 ⁇ 0.2°, 18.5 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of midostaurin crystal form C according to the present invention further has characteristic peaks at the following 2 ⁇ : 3.6 ⁇ 0.2°, 4.1 ⁇ 0.2°, 13.8 ⁇ 0.2°, 17.7 ⁇ 0.2° , 19.1 ⁇ 0.2°, 19.9 ⁇ 0.2°, 22.4 ⁇ 0.2°, 23.2 ⁇ 0.2°.
  • the midostaurin crystal form C of the present invention has substantially the same X-ray powder diffraction pattern as shown in FIG. 5 .
  • the X-ray powder diffraction pattern has the 2 ⁇ and relative intensity data shown in Table 3 below:
  • the midostaurin crystal form C according to the present invention has a melting point of 127°C as measured by a melting point apparatus.
  • the midostaurin crystal form C of the present invention has substantially the same TGA spectrum as shown in FIG. 6 .
  • Another object of the present invention is to provide a preparation method of midostaurin crystal form C, the method comprises the following steps:
  • step (2) cooling the filtrate obtained in step (1) by 0-10° C., slowly adding a poor solvent dropwise with stirring, and crystallizing to obtain midostaurin crystal form C.
  • the mass-volume ratio (g/mL) of midostaurin to benzyl alcohol is 1:2-10.
  • the volume ratio (mL/mL) of benzyl alcohol in the step (1) to the poor solvent in the step (2) is 1:6-50, and the poor solvent in the step (2) is a mixture of ethanol and water. Mix the solution, and the volume ratio (mL/mL) of the ethanol to water is 1:1.
  • the crystallization temperature is 0-10° C.
  • the dropwise addition time of the poor solvent is 3-5 h
  • the crystallization time is 1-12 h.
  • the present invention also relates to a pharmaceutical composition containing midostaurin crystal form C, the pharmaceutical composition comprising a therapeutically effective amount of midostaurin crystal form C, and one or more pharmaceutically acceptable carriers.
  • the present invention also relates to the use of the pharmaceutical composition containing midostaurin crystal form C and crystal form C for preparing a medicine for treating tumor diseases, the tumor is preferably breast cancer, colon cancer, ovarian cancer or leukemia.
  • the inventors of the present invention have found through a large number of researches that the new crystal form A, crystal form B or crystal form C of midostaurin has simple crystallization process, easy operation, low pollution, high yield, and can realize industrialized production; the crystal form of the present invention
  • the drug also has the advantages of high product purity, excellent physical and chemical properties, and good chemical stability.
  • Example 1 is the X-ray powder diffraction pattern of midostaurin crystal form A obtained in Example 1.
  • FIG. 2 is the TGA spectrum of midostaurin crystal form A obtained in Example 1.
  • FIG. 3 is the X-ray powder diffraction pattern of midostaurin crystal form B obtained in Example 5.
  • FIG. 4 is the TGA spectrum of midostaurin crystal form B obtained in Example 5.
  • FIG. 5 is the X-ray powder diffraction pattern of midostaurin crystal form C obtained in Example 9.
  • FIG. 6 is the TGA spectrum of midostaurin crystal form C obtained in Example 9.
  • the crude midostaurin used in the method of the present invention can be obtained commercially, or prepared by reacting staurostatin and benzoyl chloride under alkaline conditions according to known methods.
  • Midostaurin in the embodiment of the present invention Lin crude products are all prepared by the method of patent CN106083830A reaction.
  • the solvent used in the present invention is not particularly limited, and commercially available conventional solvents can be used.
  • the ethanol can be commercially available ethanol, including industrial ethanol, anhydrous ethanol, and the like.
  • stirring described in the method of the present invention may adopt conventional methods in the art, for example, stirring methods include magnetic stirring and mechanical stirring, and the stirring speed is 50-300 rpm/min, preferably 100-200 rpm/min.
  • the X-ray powder diffraction instrument and test conditions involved in the present invention are: X-ray diffraction instrument model Rigaku D/max-2200Cu target; operation method: scanning speed 4°/min, scanning step width 0.01°.
  • the model of the melting point apparatus involved in the present invention is: optimelt MPA100.
  • thermogravimetric analyzer TGA
  • test conditions TGA model is PerkinElmer TGA400
  • the test conditions are a heating rate of 10°C/min, and a temperature range of 30-300°C.
  • the dissolving residue (GC) detection condition of midostaurin that the present invention relates to is: instrument model: Agilent 6890; Detection method and parameter are such as table 5:
  • Fig. 1 The X-ray powder diffraction pattern of the crystal is shown in Fig. 1, and the TGA pattern is shown in Fig. 2, which is named midostaurin crystal form A in the present invention.
  • Fig. 3 The X-ray powder diffraction pattern of the crystal is shown in Fig. 3, and the TGA pattern is shown in Fig. 4. It is named as midostaurin crystal form B in the present invention.
  • the amorphous midostaurin is prepared with reference to the method in Example 3 of the patent CN101048416A, and the crystal form II of midostaurin is prepared in Example 5; the crystal form III of midostaurin is prepared with reference to the method in Example 1 of the patent CN 102639538A, and the crystal form of Midostaurin is prepared by the method in Example 2.
  • the method of Example 7 was to prepare the crystal form VIII of midostaurin
  • the method of Example 8 to prepare the crystal form of midostaurin
  • the method of Example 9 to prepare the crystal form of midostaurin
  • the method of Example 10 to prepare the crystal form of midostaurin
  • Preparation of midostaurin crystal form XII by the method of Example 11
  • preparation of midostaurin crystal form XIV by the method of Example 13 preparation of midostaurin crystal by the method of Example 15 Form XV
  • the method of Example 16 was used to prepare midostaurin crystal form XVI.
  • the preparation of crystal form II requires adding crystal form II seed crystals to obtain it stably, indicating that crystal form II is difficult to obtain spontaneously by crystallization, and there are certain risks in industrial preparation; the crystal form in patent CN102639538A
  • the preparation of III and IV requires the supercritical fluid method, which cannot be applied to conventional production, and the crystal form III described in the patent contains 3.2% residual solvent or water, and the crystal form IV contains 6.2% residual solvent or water.
  • the residual solvent is the solvent tetrahydrofuran; in the patent WO2018165071A, the crystal forms V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI are ethyl acetate solvate, hydrate, methyl isobutyl, respectively Ketone solvate, 4-heptanone solvate, methyl acetate solvate, acetone solvate, ethyl formate solvate, isopropyl acetate solvate, diethyl carbonate solvate, benzonitrile solvate, butyl acetate
  • the solvates and tert-butanol solvates, except the hydrate crystal form VI, are all solvates, and their residual solubility exceeds the standard and cannot be directly used in preparations.
  • the crystal forms A, B and C of the present invention are easy to prepare, have high yields, and can be obtained by spontaneous crystal
  • midostaurin has poor water solubility
  • melt extrusion using a twin screw extruder to mix the therapeutic compound with an inert carrier
  • melt extrusion can form solids with improved solubility and dissolution dispersion
  • heating the twin screw extruder allows easy mixing of the therapeutic compound with the carrier.
  • Midostaurin Form II has a rather high melting point (260°C), close to its decomposition temperature, which makes it difficult to apply in melt extrusion for the preparation of pharmaceutical compositions.
  • the melting point of Form III (206°C) and the melting point of Form IV (215°C) are significantly lower than those of Form II (260°C), in other words, for Form III and Form IV, the decomposition temperature is significantly higher than that of Form III and Form IV. Melting temperature, so during melt extrusion, intimate mixing of Forms III and IV with pharmaceutically acceptable excipients can be accomplished at lower temperatures while reducing the risk of decomposition; Form B and Form C have lower melting points than Form III and Form IV.
  • the melting point of Form A is 196°C
  • the melting point of Form B is 198°C
  • the melting point of Form C is 127°C.
  • the intimate mixing of Form A, Form B and Form C with pharmaceutically acceptable excipients can be accomplished at a lower temperature than Form II while reducing the risk of decomposition.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne de nouvelles formes cristallines A, B et C de midostaurine, leur procédé de préparation et leur utilisation. Les formes cristallines présentent d'excellentes propriétés en termes de stabilité physique et chimique et d'adaptabilité au traitement ; et le processus de cristallisation est simple et pratique à utiliser, et la production industrielle peut être réalisée.
PCT/CN2021/133470 2020-12-31 2021-11-26 Nouvelle forme cristalline de midostaurine, son procédé de préparation et son utilisation WO2022142914A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011614974.0 2020-12-31
CN202011614974.0A CN112812129A (zh) 2020-12-31 2020-12-31 米哚妥林的新晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
WO2022142914A1 true WO2022142914A1 (fr) 2022-07-07

Family

ID=75855497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/133470 WO2022142914A1 (fr) 2020-12-31 2021-11-26 Nouvelle forme cristalline de midostaurine, son procédé de préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN112812129A (fr)
WO (1) WO2022142914A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112812129A (zh) * 2020-12-31 2021-05-18 浙江海正药业股份有限公司 米哚妥林的新晶型及其制备方法和用途

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296110A2 (fr) * 1987-06-15 1988-12-21 Ciba-Geigy Ag Dérivés de staurosporine substitués à l'azote du méthylamino
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
CN101010082A (zh) * 2004-08-31 2007-08-01 诺瓦提斯公司 米哚妥林用于治疗胃肠道基质瘤的用途
CN101048416A (zh) * 2004-11-05 2007-10-03 诺瓦提斯公司 有机化合物
CN102639538A (zh) * 2009-11-30 2012-08-15 诺瓦提斯公司 N-苯甲酰基-星孢素的多晶型形式iii和iv
WO2018165071A1 (fr) * 2017-03-06 2018-09-13 Teva Pharmaceutical Works Ltd. Formes à l'état solide de midostaurine
WO2019215759A1 (fr) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad Procédé amélioré de préparation de midostaurine
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
WO2020200945A1 (fr) * 2019-03-29 2020-10-08 Procos S.P.A. Procédé de préparation de midostaurine à pureté élevée
WO2020261293A1 (fr) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Procédé de préparation de midostaurine
CN112812129A (zh) * 2020-12-31 2021-05-18 浙江海正药业股份有限公司 米哚妥林的新晶型及其制备方法和用途

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296110A2 (fr) * 1987-06-15 1988-12-21 Ciba-Geigy Ag Dérivés de staurosporine substitués à l'azote du méthylamino
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
CN101010082A (zh) * 2004-08-31 2007-08-01 诺瓦提斯公司 米哚妥林用于治疗胃肠道基质瘤的用途
CN101048416A (zh) * 2004-11-05 2007-10-03 诺瓦提斯公司 有机化合物
CN102639538A (zh) * 2009-11-30 2012-08-15 诺瓦提斯公司 N-苯甲酰基-星孢素的多晶型形式iii和iv
WO2018165071A1 (fr) * 2017-03-06 2018-09-13 Teva Pharmaceutical Works Ltd. Formes à l'état solide de midostaurine
WO2019215759A1 (fr) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad Procédé amélioré de préparation de midostaurine
WO2020200945A1 (fr) * 2019-03-29 2020-10-08 Procos S.P.A. Procédé de préparation de midostaurine à pureté élevée
WO2020261293A1 (fr) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Procédé de préparation de midostaurine
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN112812129A (zh) * 2020-12-31 2021-05-18 浙江海正药业股份有限公司 米哚妥林的新晶型及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG LIPING;ZHUANG YIBIN;SUN KUNLAI;ZHU WEIMING: "Synthesis and Cytotoxicity of Halogenated Derivatives of PKC-412", CHINESE JOURNAL OF ORGANIC CHEMISTRY, vol. 34, no. 8, 15 August 2014 (2014-08-15), pages 1603 - 1608, XP055948888, ISSN: 0253-2786, DOI: 10.6023/cjoc201403046 *

Also Published As

Publication number Publication date
CN112812129A (zh) 2021-05-18

Similar Documents

Publication Publication Date Title
EP2909182B1 (fr) Préparation d'un inhibiteur de mek et formulation le contenant
KR20150036336A (ko) 타이로신 키나제 억제제 다이말리에이트의 결정형 아이 및 그의 제조 방법
US8933114B2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
TW201704234A (zh) 氮雜二環式化合物之結晶
WO2022142914A1 (fr) Nouvelle forme cristalline de midostaurine, son procédé de préparation et son utilisation
JP2022517675A (ja) Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用
WO2018157803A1 (fr) Formes cristallines de vénétoclax et leur procédé de préparation
EP3216790B1 (fr) Forme cristalline de bisulfate inhibiteur de kinase jak et procédé de préparation correspondant
KR101684053B1 (ko) 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
EP3805229B1 (fr) Sel d'un composé de pyrimidine à noyau condensé, sa forme cristalline, son procédé de préparation et son utilisation
WO2017063572A1 (fr) Nouvelle forme cristalline d'agent induisant l'apoptose de cellules et son procédé de préparation
WO2015176591A1 (fr) Sels de betrixaban, procede de preparation et utilisation de ceux-ci
WO2018133823A1 (fr) Forme cristalline de bisulfate d'inhibiteur de kinase jak et son procédé de préparation
CN108778282B (zh) 一种GnRH受体拮抗剂的结晶形式及其制备方法
WO2018072742A1 (fr) Forme cristalline de base libre de dérivé d'imidazo-isoindole et son procédé de préparation
US20040063782A1 (en) Bicalutamide forms
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
JP2019509306A (ja) Ｊａｋ関連疾患の治療又は予防に用いる薬物の塩酸塩の結晶形及びその製造方法
WO2018103027A1 (fr) Forme cristalline de tipifarnib, procédé de préparation et composition pharmaceutique associés
JP4498679B2 (ja) 結晶性イソキサゾール誘導体およびその医薬製剤
WO2016110243A1 (fr) Forme cristalline d'un malate d'un inhibiteur de tyrosine kinase et procédé de préparation de ce dernier
EP1051398B1 (fr) Forme thermodynamiquement stable d'un acide (r)-3- (4-fluorophenyl) sulfonyl]amino] -1,2,3,4-tetrahydro -9h-carbazole -9-propionique (ramatrobane)
WO2020083188A1 (fr) Forme cristalline de maléate d'inhibiteur de tyrosine kinase et son procédé de préparation
WO2016050134A1 (fr) Composé l-proline d'un inhibiteur du cotransporteur sodium-glucose de type 2, ainsi que monohydrate et cristal du composé l-proline
WO2018233591A1 (fr) Sel de dérivé de benzopipéridine et forme cristalline de celui-ci, procédé de préparation du sel et de la forme cristalline de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21913656

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21913656

Country of ref document: EP

Kind code of ref document: A1